Overview
As the biologics market continues to expand and diversify, so too must regulatory processes. With technological advances enabling more powerful toolsets designed specifically to develop biologics such as recombinant DNA-derived therapeutic proteins, adherence to cGMP (Current Good Manufacturing Practices) compliance has never been more important for developers of biopharmaceuticals.
